{
  "id": 12619335,
  "title": "UAE pharmaceutical manufacturer Mubadala Bio launches two treatments for immune disorders",
  "url": "https://urgent.news/2026/10/07/uae-pharmaceutical-manufacturer-mubadala-bio-launches-two-treatments",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T11:07:34.000Z",
  "source": {
    "name": "Gulf News",
    "slug": "gulf-news",
    "url": "https://gulfnews.com/uae/government/uae-pharmaceutical-manufacturer-mubadala-bio-launches-two-treatments-for-immune-disorders-1.500701725"
  },
  "original_language": "en",
  "account": "The pharmaceutical manufacturer Mubadala Bio in the UAE has introduced two new treatments for immune-mediated diseases, adalimumab and ustekinumab. Both therapies are produced at Mubadala Bio's BioVenture Healthcare facility, which bolsters the company's portfolio of biologic therapies and contributes to the country's efforts to improve access to advanced treatment options. Adalimumab, a monoclonal antibody, targets tumor necrosis factor (TNF) to combat inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. Ustekinumab inhibits inflammatory pathways involving interleukins 12 and 23 and is used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The launch of these therapies aligns with Mubadala Bio's goal of strengthening the UAE's healthcare ecosystem, enhancing access to essential biologic treatments, and fostering a resilient pharmaceutical industry. The new medicines require a prescription and should only be prescribed or discussed by licensed healthcare professionals. Mubadala Bio's Chief Executive Officer, Dr. Esam Mohamed, emphasized the importance of the addition in broadening access to specialized treatment options and aiding healthcare providers in delivering advanced care. Mubadala Bio's Deputy Chief Executive Officer, Hamad Al Marzouqi, highlighted the company's growing portfolio of biologic therapies as evidence of its commitment to developing and localizing innovative treatments, thus bolstering the UAE's pharmaceutical industry.",
  "summary": "Mubadala Bio, the UAE-based national pharmaceutical manufacturing company focused on strengthening the country’s pharmaceutical industry ecosystem, has launched two new treatments for immune-mediated diseases — adalimumab and ustekinumab — through its manufacturing facility, BioVenture Healthcare. The launch strengthens the company’s portfolio of biologic therapies and supports its efforts to…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}